

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Appl.: Rakoczy, et al. : Group Art Unit: 1635
Serial No: 09/065,082 : Appl. Ref. No: GRI-010
Filed: July 16, 1998 : Examiner: S. McGarry
Title: HYALURONIC ACID AS DNA CARRIER FOR GENE THERAPY
AND VEGF ANTISENSE DNA TO TREAT ABNORMAL RETINAL
VASCULARIZATION

COVER LETTER

U.S. Patent and Trademark Office
International Preliminary Examining Authority
BOX PCT
Washington, D.C. 20231

Sir/Madam:

In response to the Office Action dated March 15, 2000, enclosed for filing are the following:

1. (Revised) Declaration for Sequence Listing
2. Postcard


Respectfully submitted,
ARTER & HADDEN


Viviana Amzel, Ph. D.
Reg. No. 30930
Attorney for Applicant(s)

Date: _____

Citicorp Building
725 South Figueroa Street
Los Angeles, California 90017
213-430-3520 Direct Ph.
213-617-9255 Fax

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington D C 20231 on 3-21-00 by Jenny R. Wilson.



SIGNATURE

RECEIVED
APR - 7 2000
PCT
1600 MAIL ROOM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rakoczy et al. : Appl. Ref.: **GRI-010**
 Serial. No: 09/065,082 : Examiner: **S. McGarry**
 Filing Date: 3 Aug. 1999 : Group Art Unit: **1635**
 For: **HYALURONIC ACID AS DNA CARRIER FOR GENE THERAPY AND VEGF
 ANTISENSE DNA TO TREAT ABNORMAL RETINAL VASCULARIZATION**

#16
 M.Q.D
 4/8/00


DECLARATION

Assistant Commissioner of Patents & Trademarks
 Washington, DC 20231

Sir\Madam:


I, Viviana Amzel, hereby state that the contents of the paper and computer readable copies of the enclosed Sequence Listing section submitted on February 2, 2000 and of the sequences contained in the originally filed US patent application, the Australian and PCT priority applications, and the amendments made with the responses filed in the PCT phase (copies were enclosed with the papers filed with documents at the time of entering the US National Phase) are the same. The enclosed Sequence Listing (paper and computerized forms) include no new matter and the sequences therein, to the best of applicant's knowledge, are the same as the sequences in the original Australian, PCT and US patent applications as filed, and the amendments entered during the PCT phase.

Respectfully submitted.
 ARTER & HADDEN


 Viviana Amzel, Ph. D.
 Agent for Applicant

Citicorp Building
 725 South Figueroa St.
 Suite 3400
 213-430-3520 Ph.
 213-617-9255 Fax

I hereby certify that this paper or fee is being deposited with the United States Postal Service "First Class Mail" service under 37 CFR 1.8 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington DC 20231, on March 21, 2000, by Jenny Rebecca Wilson.


 SIGNATURE

RECEIVED
 APR - 7 2001
 1600 MAIL ROOM